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Background: The purpose of this study was to evaluate the efficacy and tolerability of weekly docetaxel, cisplatin,
and S-1 (weekly TPS) as induction chemotherapy for patients with locally advanced head and neck squamous cell
carcinoma (HNSCC).
Methods: A total of 35 patients with previously untreated, locally advanced HNSCC were enrolled. Seven patients
(20%) were diagnosed with stage III HNSCC and 28 patients (80%) were diagnosed with stage IV. Induction
treatment included 30 mg/m2 docetaxel on day 1 and 8, 60 mg/m2 cisplatin on day 1, and 70 mg/m2 S-1 on days
1 to 14. The regimen was repeated every 21 days. After three courses of induction chemotherapy, patients received
concurrent chemoradiotherapy.
Results: Among the 35 patients, 30 (85.7%) completed induction chemotherapy. The response to induction
chemotherapy was as follows: nine patients (25.7%) achieved a complete response (CR) and the overall response
rate (ORR) was 85.7%. Grades 3–4 toxicity during induction therapy included neutropenia (28.5%), neutropenic fever
(8.5%), and diarrhea (17.1%). After completion of concurrent chemoradiotherapy, the CR rate was 62.8% and the
partial response (PR) was 22.8%. Estimates of progression-free and overall survival at 2 years were 73.2% and 79.3%,
respectively.
Conclusions: Weekly TPS is a promising regimen that is well-tolerated, causes minimal myelosuppression and is
effective as an outpatient regimen for locally advanced HNSCC.
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Head and neck squamous cell carcinoma (HNSCC)
ranks sixth among the most common cancers, account-
ing for approximately 5% of all cases of cancer [1]. The
disease is potentially curable at an early stage, but 40%
to 50% of patients present with locally advanced disease
[2]. Meta-analysis of adjuvant chemotherapy in head and
neck cancer suggests an increase absolute survival [3-5].
Combined modality approaches have been developed in
an effort to enhance loco-regional disease control,
reduce distant metastatic spread, and improve survival
in patients with inoperable head and neck cancer [6-8].
Contrary to the usual pattern of failure, several studies
have shown that in patients treated with CCRT, there
was an increase in systemic relapse due to a lack of sys-
temic control [9,10]. In this regard, interest in the use of
induction chemotherapy has been shown. The use of
induction chemotherapy is based on two hypotheses.
One involves the better delivery of the drug in untreated,
well-vascularized tumors, and the second involves the
eradication of the micrometastatic disease with systemic-
ally active doses of chemotherapy [11]. In addition, a
patient who is treatment-naïve may be more tolerant of
the adverse effects of chemotherapy treatment compared
with a patient who has received prior radiation [12].
Even though several meta-analyses failed to reveal any
significant improvement in survival using adjuvant chemo-
therapy [4,13], two phase II trials have explored and
highlighted the role of induction chemotherapy using
three-drug combination chemotherapy regimens compris-
ing fluorouracil, cisplatin, and a taxane [14,15]. Subse-
quently, phase III trials of a TPF regimen (using docetaxel)
significantly improved the rate of progression and overall
survival not only in patients with unresectable HNSCC
[16], but also in localized HNSCC followed by CCRT [17].
We also previously reported a 95.4% overall response rate
and 88.7% progression-free survival at 2 years in a phase II
study using TPF induction chemotherapy in locally
advanced HNSCC [18].
Therefore, the TPF regimen has become the standard
treatment for induction or palliative treatment of ad-
vanced HNSCC. However, the TPF regimen has been
shown to cause severe myelotoxicity (e.g., grades 3–4
neutropenia in 80–90% of patients). Docetaxel is widely
used to treat solid tumors such as breast cancer, lung
cancer, gastric cancer and esophageal cancer. To reduce
the associated toxicity, several studies have suggested
that weekly doses of docetaxel may help reduce bone
marrow suppression relative to 3-week regimens, which
show similar efficacy [19-21]. However, there has been
no report of use of these treatment regimens in head
and neck cancer patients.
S-1 is an oral fluoropyrimidine derivative that was
developed in Japan, based on the concept of biochemicalmodulation. It consists of the following three compo-
nents in a molar ratio of 1:0.4:1; tegafur, a prodrug that
is slowly metabolized to 5-fluorouracil; gimeracil, which
reversibly inhibits dihydropyrimidine dehydrogenase, the
rate-limiting 5-fluorouracil-degrading enzyme, use of
which results in an increase in the plasma concentration
of 5-fluorouracil; and oteracil potassium, which is dis-
tributed in high concentrations in gastrointestinal tissue
and inhibits phosphorylation of 5-fluorouracil, reducing
its gastrointestinal toxicity. S-1 was developed to achieve
enhanced efficacy with lower toxicity when compared to
conventional 5-fluorouracil derivatives [22]. The oral ad-
ministration of S-1 enables chronic daily dosing and
results in effects similar to continuous 5-fluorouracil
infusion without the complications and inconvenience
associated with central venous catheter access and S-1
offers the potential for more convenient outpatient
treatment.
Therefore, this study was conducted to evaluate the
efficacy and tolerability of weekly docetaxel and TS-1
compared to 3-week docetaxel and intravenous 5-FU
treatment, with cisplatin as an induction chemotherapy,
for locally advanced HNSCC.
Methods
Patients
Patients were eligible if they had locally advanced stage III
or IV squamous cell carcinoma of the larynx, oropharynx,
or hypopharynx. Patients at least ≥18 years old with ad-
equate bone marrow and organ function were included in
this study (i.e., absolute neutrophil count ≥1,500/μL,
platelets ≥100,000/μL, serum bilirubin <2.0 mg/dL, cre-
atinine <1.5 mg/dL, and serum transaminase levels less
than twice the upper limit of normal). Patients were ex-
cluded from the study if they had received previous
chemotherapy. Other exclusion criteria included history
of another malignancy; pregnancy or lactation; current
or history of distant metastasis; history of clinically
significant cardiac disease (serious arrhythmia, heart
failure, myocardial infarction, or unstable angina)
within the last 6 months; active serious infection; or a
psychiatric illness that would preclude obtaining
informed consent. Patients with nasopharyngeal carcin-
oma were also excluded from the study.
Pretreatment staging involved examination of the ears,
nose, and throat by an otolaryngologist, as well as a
computed tomographic (CT) scan or magnetic reson-
ance imaging (MRI) of the primary tumor site and neck.
To detect other primary aerodigestive tract malignan-
cies, patients underwent a CT scan of the chest and an
esophagogastroduodenoscopy or pharyngoesophagram.
Before radiation therapy, all patients received a dental
examination to avoid unexpected osteonecrosis or osteo-
myelitis associated with radiation.
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being enrolled in the study, which was approved by the
institutional review board of each participating hospital.
Induction chemotherapy
Docetaxel (30 mg/m2) was given as a 1-h intravenous in-
fusion on days 1 and 8. Cisplatin (60 mg/m2) was given
as a 3-h intravenous infusion on day 1. S-1 was given or-
ally twice daily, at 70 mg/m2, for 14 consecutive days.
The cycles were repeated every 3 weeks. Patients re-
ceived further cycles of chemotherapy only when the ab-
solute neutrophil count was ≥1,000/mm3 and the
platelet count was ≥100,000/mm3. Toxicity was graded
according to the National Cancer Institute Common
Toxicity Criteria (NCI-CTC), version 3.0. Dose modifi-
cations were determined based on hematological and
non-hematological toxicity. The dose of docetaxel was
reduced by 20% after any episode of febrile neutropenia
or grade 4 neutropenia lasting more than 5 days or for
grade 4 thrombocytopenia and grade 3 or 4 non-
hematological toxicity, except alopecia. If these compli-
cations developed after docetaxel dose adjustment, the
S-1 dose in the next cycle was reduced by 20%. The dose
of docetaxel on day 8 was interrupted in cases of grade 2
or higher neutropenia and thrombocytopenia and post-
poned to day 10. Docetaxel treatment on day 10 was
withheld in cases of grade 4 neutropenia and grade 3 or
4 thrombocytopenia. All patients received pre- and post-
cisplatin intravenous hydration. Standard intravenous
premedications with dexamethasone, diphenhydramine,
and ranitidine were administered 30 min before docetaxel
infusion to prevent hypersensitivity reactions. A prophy-
lactic antibiotic (levofloxacin 500 mg) was given orally for
5 days of each chemotherapy cycle. As supportive treat-
ment for grade 4 neutropenia and grade 3 or 4 febrile neu-
tropenia, granulocyte colony-stimulating factor (G-CSF)
and antibiotics were given at the investigators’ discretion.
Concurrent chemoradiotherapy
After three cycles of induction chemotherapy, patients
had radiotherapy using 6 MV photon beams produced
by linear accelerator having multi-leaf collimator. All pa-
tients had CT scanning for radiation treatment planning
at supine position with a thermoplast immobilization
mask. Primary tumor site and upper neck node bearing
areas were irradiated by two parallel opposing fields with
half beam technique, and lower neck and supraclavicular
nodes by matched anterior one field. The spinal cord
was shielded after 44 or 45 Gy, and then treatment fields
were gradually reduced so that the volume containing
the gross disease was irradiated with a curative dose. All
patients were treated with standard radiotherapy tech-
nique in daily fraction of 1.8 or 2 Gy, 5 days per week.
The gross neck node had a boost irradiation with a9 MeV or 12 MeV electron beam. The primary tumor
site and gross neck node area received 65 to 70 Gy over
7 to 8 weeks. A minimum of 45 Gy was delivered to
clinically uninvolved neck nodes and supraclavicular
nodes.
Definite irradiation was scheduled with concurrent
administration of cisplatin in all patients except for those
whose performance status or residual toxicities pre-
cluded the co-administration of chemotherapy. Cisplatin
was given every 3 weeks at a dose of 100 mg/m2,
depending on creatinine clearance. Doses of cisplatin
were delayed if there was evidence of dehydration, renal
toxicity, neurotoxicity or ototoxicity. For patients with
grades 3–4 mucositis or dysphagia, radiation therapy
was delayed until recovery to less than grade 2 toxicities.
Follow-up and evaluation
After three cycles of induction chemotherapy and 6–8 -
weeks after completion of CCRT, clinical responses were
assessed. Patients underwent examination by an oto-
laryngologist, as well as CT or MRI imaging of the pri-
mary tumor and neck. A biopsy of the primary site was
recommended if possible. Tumor response was assessed
according to the Response Evaluation Criteria in Solid
Tumors (RECIST). For all patients with a complete re-
sponse (CR) on the physical examination and CT or
MRI scans, an [18 F] fluorodeoxyglucose positron emis-
sion tomography (18 F-FDG-PET) scan was performed as
a confirmation at 3 months after CCRT. When CCRT
was completed, patients were observed on a monthly
basis by a physician examination to evaluate the status
of the disease and toxicity; CT or MRI scanning was
performed every 3 months until disease progression.
Toxicity was assessed according to the NCI-CTC, ver-
sion 3.0. Quality of life (QOL) measures were assessed
using the European Organization for Research and
Treatment of Cancer Core Quality of Life questionnaire
(EORTC QLQ C-30 version 3) at baseline and after
three cycles of induction chemotherapy. During radi-
ation therapy, the toxicities were evaluated by a phys-
ician every 2 weeks.
The dose intensity was calculated as the ratio of the
total dose per square meter of body surface area divided
by the total treatment duration (presented as mg/m2/
week). In this calculation, the end of treatment was con-
sidered to be 21 days after day 1 of the last cycle of
chemotherapy. The relative dose intensity was calculated
as the ratio of the dose intensity actually delivered to
that planned.
Statistical analysis
The primary endpoint was objective response, and sec-
ondary endpoints were safety, QOL, progression-free
survival (PFS), and overall survival (OS). The study was
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sample size of 35 patients was required to accept the hy-
pothesis that the true response rate was greater than
90% with an 85% power and to reject the hypothesis that
the response rate was less than 70% with 5% significance.
Initially we planned to enroll 18 patients in the first
stage. If 13 or more responses were observed, we
planned to continue to the second stage for a total of 32
patients in the analysis. Assuming a dropout rate of 10%,
the total number of enrolled patients needed was calcu-
lated to be 35. The OS was measured from the start of
chemotherapy until the date of death or the last con-
firmed date of survival. The PFS was defined as the time
from the start of chemotherapy to the first appearance
of progressive disease or death from any cause. The
survival analysis was performed using the SPSS software
(version 18.0; SPSS Inc., Chicago, IL, USA), and 95%
confidence intervals (CIs) were calculated for all relevant




Based on the previously described Simon’s two-stage de-
sign, 18 patients who met the criteria were enrolled, and
15 patients (83.3%) achieved an objective response rate
(ORR). Therefore, the study proceeded to the next stage,
and a total of 35 patients were enrolled.
Patient baseline characteristics are given in Table 1.
Thirty-five patients with locally advanced HNSCC were
enrolled between October 2008 and October 2011 as the
intention-to-treat (ITT) population. The enrolled popu-
lation consisted of 33 males and two females, with a me-
dian age of 57 years (range, 29–72 years). Most patients
(80%) had stage IV cancer; 20% had stage III HNSCC. The
most common primary tumor site was the oropharynx
(48.6%), followed by the hypopharynx (28.6%) and the
larynx (22.9%). All 17 patients with oropharyngeal cancer
were smokers. Twelve of these patients had evaluable
specimens, none of which were positive for human papil-
lomavirus (HPV) DNA by in situ hybridization (ISH).
Treatment
A total of 97 cycles of weekly TPS therapy were given to
35 patients, and 30 completed the scheduled CCRT.
Three patients received only one cycle and two patients
received two cycles of TPS due to toxicological effects.
The median duration from day 1 of cycle 1 to day 1 of
cycle 3 of induction chemotherapy was 6.6 weeks (range,
5.8–9.4 weeks), and the median duration from day 1 of
cycle 3 of chemotherapy to day 1 of CCRT was 5.3 weeks
(range, 2.5–11.2 weeks). The mean dose intensities rela-
tive to the target dose of docetaxel, cisplatin, and TS-1
were 97.7%, 98.6%, and 97.7%, respectively. The mostcommon reasons for a decrease in dose intensity were
neutropenia and diarrhea. During CCRT, the mean dose
intensities relative to the target dose of cisplatin was
69.6%. RT was interrupted in 10 patients (33.3%); of
these, six had grades 3–4 mucositis, two had grade 2
renal toxicity, and two had grade 3 fatigue. However, RT
was continued and completed in these patients after no
more than 2 weeks of rest.
Response and survival
Thirty patients (85.7%) were evaluable for a response.
The five patients that were not evaluable were included
in the ITT analysis and kept in the denominator for
calculation of the response rate. Five patients
discontinued induction chemotherapy; three due to ad-
verse events (grade 4 neutropenia or febrile neutro-
penia), one was lost to follow-up (this patient showed
a near clinical CR), and one died of asphyxia associated
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cancer.
After three cycles of induction chemotherapy, 30
patients (85.7%) achieved an objective response (CR in 9
patients, 25.7% [95% CI 11.2–40.2%]; and a partial
response [PR] in 21 patients, 60% [95% CI 43.8–76.2%]).
Consistent response rates across primary tumor sites
were observed in a subgroup analysis and included the
oropharynx (CR 17.6%, PR 70.6%), hypopharynx (CR
30%, PR 50%), and larynx (CR 37.5%, PR 50%). After
sequential CCRT, 22 patients (62.9%) achieved a CR
(95% CI 46.8–78.9%) and eight (22.8%) achieved a PR
(95% CI 8.9–36.8%) (Table 2). The mean follow-up dur-
ation was 30.3 months. The estimated 2-year PFS and
OS rates were 73.2% (95% CI 52.4–93.6%) and 79.3%
(95% CI 58.4–99.6%), respectively (Figure 1).Table 2 Response to induction chemotherapy and
chemoradiation therapy
Primary lesion (n = 35) Lymph node (n = 25)
Response No. % No. %
After induction chemotherapy
CR 18 51.4 7 28
PR 11 31.4 13 52
SD 1 2.9 1 4
PD 0 0 0 0
Non-assessable 5 14.2 4 16








CR 24 68.6 17 68
PR 6 17.1 4 16
SD 0 0 0 0





ORR (CR + PR)
No. 30
% 85.7
Abbreviations: LN, regional neck lymph nodes; CR, complete response; PR,
partial response; SD, stable disease; PD, progressive disease; ORR, overall
response rate.Quality of life and symptom response
Global QOL was assessed at baseline and at 9 weeks
(after 3 cycles of induction chemotherapy) using the
EORTC QLQ C-30, version 3. Completed questionnaires
were available for 30 patients (Table 3). There was a
non-significant decrease in global QOL, from a median
score of 56.1 at baseline to 53 at 9 weeks. Emotional
functioning was significantly impaired, but other func-
tional QOL scores (e.g., physical, role, cognitive, and
social functioning) showed no significant differences.
There were no significant differences in most treatment-
related symptoms, except nausea and vomiting. Nausea
and vomiting were significantly increased.
Pattern of first relapse
Among 30 patients who showed a complete or partial
response after CCRT, five had locoregional recurrence.
Four of the five patients showed a PR and one showed a
CR after CCRT. All five patients showed initially ad-
vanced stage IV disease. Except one patient who showed
PD among the patients showing CR, 21 patients had no
recurrence until this analysis was done. Among the pro-
gressive patients from PR, One patient underwent
salvage surgery and chemotherapy, three received only
palliative chemotherapy, and one refused additional
treatment. Distant relapse was not observed in this
study.
Toxicity
The toxicity of weekly induction TPS chemotherapy was
assessed in all 35 patients (Table 4). Grades 3–4 neutro-
penia occurred in 28.5% of patients, and 8.5% developed
febrile neutropenia during induction chemotherapy. The
most common grades 3–4 nonhematologic toxicities were
diarrhea (17.1%), anorexia/nausea/vomiting (11.4%), and
mucositis (8.5%). Anorexia/nausea/vomiting, fatigue/as-
thenia, mucositis, and diarrhea of less than grade 2 devel-
oped in 74.2%, 65.7%, 42.8%, and 42.8% of patients,
respectively.
Discussion
The TPF regimen remains the standard induction chemo-
therapy option for patients with advanced HNSCC based
on their synergistic effect. Longer overall and progression-
free survival and a non-significant reduction in overall
toxic effects were evident in the TPF group as compared
with PF [17]. However, there was more myelotoxicity in
the TPF group (83%) than in the PF group (56%), indicat-
ing a clear need for regimens with improved tolerability
and lower toxicity.
This study was designed to establish a safe and toler-
able outpatient regimen using docetaxel for induction
chemotherapy for HNSCC. This study was designed to
establish a safe and tolerable outpatient regimen using
PFS
OS
Figure 1 Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) for all patients. The 2-year PFS & OS rate was
79.3% (95% CI 58.4 ~ 99.6%) and 73.2% (95% CI 52.4 ~ 93.6%).
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phase I/II trials using 3 weekly TPF in advanced
HNSCC, docetaxel was given at a dose of 75 mg/m2
every 3 weeks and showed 95% of the rates of grade 3–4
neutropenia and 19% of febrile neutropenia [15]. To
reduce the myelosuppresion, Rapidis et al. reported the
result using biweekly docetaxel (40 mg/m2) with
cisplatin and 5-FU, and the rates of grades 3–4 neutro-
penia was 37% [23]. This results suggested that biweekly
or weekly docetaxel could be substituted for 3 weekly
regimen if the response are similar. Not only in HNSCC,
weekly docetaxel has been studied in variable solid
tumors such as gastric cancer, ovarian cancer and lung
cancer because of its safety compared with 3 weekly
docetaxel regimen [24-28]. In a literature-based meta-
analysis of all randomized clinical trials of weekly versus
three-weekly docetaxel in advanced NSCLC, a significant
homogenous advantage in favor of weekly docetaxel was
found regarding grades 3–4 neutropenia, with an abso-
lute benefit of 15% to 19%.
In another way to modify 3 weekly TPF regimen there
is an increasing trend for the substitution conventional
5-fluorouracil for oral prodrugs, including S-1 and
capecitabine, in chemotherapy regimens. S-1 showed
response rates of 28.8% to 46.2% with an acceptable
toxicit in phase II studies of advanced and recurrentHNSCC [29,30]. Therapy with S-1 plus cisplatin in a
phase I/II study was effective and showed acceptable
toxicities for advanced/recurrent HNSCC [31]. The S-1/cis-
platin combination was also used as induction therapy
for advanced HNSCC stage III/IV cancer, and a re-
sponse rate of 89.7% was reported [32]. To substitute
the S-1 for continuous 5-FU infusion in TPF regimen,
the studies were performed in advanced gastric cancer
patients in advance. According to these trials, the
recommended dose for TPS were 60/60/40 (bid)
mg·m2/d in each [33-35].
Based on these dosese, we conducted the study using
TPS for HNSCC. To reduce the hematologic toxicity, we
modified the TPS regimen using weekly docetaxel at a
dose of 30 mg/m2. In a result, the most common
hematological and non-hematological toxicities were
reduced showing 28.5% of grade 3–4 neutropenia and
17.1% of diarrhea, which were lower than previous
results [15,36]. Many patients with advanced HNSCC
experience dysphagia from the primary tumor, and diffi-
culty in swallowing capsules containing S-1 may also
occur. However, in the present study there was no diffi-
culty or failure in attempts at swallowing S-1 capsules,
and mucositis was tolerable. Furthermore, there were no
significant changes in most QOL scores as assessed by
the EORTC QLQ, except emotional functioning and
Table 4 Acute hematologic and nonhematologic adverse
events during induction chemotherapy and concurrent
chemoradiotherapy
Grade 1-2 Grade 3-4
No. % No. %
Hematologic
Neutropenia 9 25.7 10 28.5
Neutropenic fever 0 0 3 8.5
Anemia 22 62.8 1 2.8
Thrombocytopenia 10 28.5 1 2.8
Nonhematologic
Anorexia/Nausea/Vomiting 26 74.2 4 11.4
Fatigue/Asthenia 23 65.7 1 2.8
Mucositis/Odynophagia 15 42.8 3 8.5
Diarrhea 15 42.8 6 17.1
Neuropathy 4 11.4 0 0
Nephropathy 5 14.2 0 0
Note. Adverse events were graded according to the National Cancer Institute
Common Toxicity Criteria, version 3.0.
Table 3 Quality of life scores at baseline and at
completion of induction chemotherapy (scored by















Physical functioning 84.7 89.7 NS
Role functioning 89 90.9 NS
Emotional
functioning




Social functioning 77.1 83.8 NS
Symptom scales/items
Fatigue 19.5 24.5 NS
Nausea and
vomiting
3.4 9.7 < 0.05
Pain 17.2 10.3 NS
Dyspnea 11.4 11.4 NS
Insomnia 16 16 NS
Appetite loss 17.2 29.8 NS
Constipation 6.8 11.4 NS
Diarrhoea 3.4 10.3 NS
Financial difficulties 26.4 36.7 NS
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recurrent HNSCC have been reported [37]. In this phase
I study, they recommended the phase II dose of TPS as 70/
70/60 mg·m2/d every 3 weeks. However, the rate of grade
3–4 neutropenia was 75% at the recommended dose.
The efficacy of our regimen also showed promise.
Patients enrolled in this study had significantly advanced
disease; 28 (80%) had stage IV disease, while only seven
(20%) had stage III disease. The ORR was 85.7% after in-
duction chemotherapy (CR in 25.7% and PR in 60%) and
CR rates increased after CCRT; i.e., a CR rate of 62.9%
and PR rate of 22.8%. These results are comparable to
previous reports of induction chemotherapy. In the
study by Rapidis et al. [15,23], the ORR after induction
chemotherapy was 78.1% (CR in 24.4% and PR in
53.7%). Vermorken et al. [16] reported an ORR after in-
duction chemotherapy of 68% (CR 8.5% and PR 59.3%).
In the present study, all patients who completed the
induction chemotherapy (85.7%) showed CR or PR.
Therefore, the response rate was 100%. Unexpectedly,
five patients dropped out of this study. One patient
showed near CR, but he was lost to follow up without
response evaluation. Four patients refused further
chemotherapy due to grades 3–4 neutropenia or neutro-
penic fever.
The most common pattern of relapse was locoregional
failure without distant metastasis. In fact, four patients
who showed recurrence had PR after CCRT; they also
had progressive disease during the follow-up period.
Only one patient showed definitive recurrence from CR
after CCRT. This suggests that a weekly TPF regimen is
promising in terms of preventing distant metastasis.
Even though radiation was completed after recovery of
toxicity during CCRT, radiation interruption may be an
explanation of locoregional failure. Cisplatin based
CCRT has been a standard regimen for head and neck
cancer, however the toxicities are considerable. Based on
RTOG 9501 [38], which study compared the benefit of
postoperative CCRT versus RT, the radiotherapy was
delivered in 80% of patients and the planned cisplatin
compliance was only 61%. In our study, ten (77%)
patients were interrupted the planned RT, but all these
patients could receive the planned RT dose after recov-
ery and seven patients showed CR. Among three
patients who had PR after CCRT, one patient showed
progressive disease during follow up period. Thus a fur-
ther study aiming to reduce the toxicity during CCRT
using cetuximab or weekly cisplatin is warranted.
Even though our data suggest a feasible option for ad-
vanced HNSCC, this study has several limitations. First,
the higher proportion of patients with oropharyngeal
cancer may have affected the response. All 17 patients
were smokers, and 12 (70.5%) who had evaluable sam-
ples were negative for HPV. Therefore, it seemed that
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this study. Second, the dose and number of planned cis-
platin treatments during CCRT had to be reduced due
to toxicological responses such as mucositis. As men-
tioned above, an optimal regimen during CCRT should
be evaluated after induction chemotherapy. In addition,
chronic toxicity was not evaluated because the aim of this
study was to determine the efficacy of a weekly TPS regi-
men. However, a study of chronic toxicity is needed to clar-
ify the effects on the quality of life of long-term survivors.
Conclusion
In conclusion, a weekly docetaxel, cisplatin, and S-1
combination as an induction regimen showed promising
efficacy and safety in locally advanced HNSCC patients.
Myelosuppression, which is the most serious and com-
mon complication of TPF regimens, was notably low
using this regimen. While relatively few patients were in-
cluded in this study, the results suggest that a weekly
TPS regimen represents an alternative to TPF as an out-
patient regimen for the treatment of locally advanced
HNSCC. Our findings indicate that a phase III trial of
the efficacy of this treatment regimen compared to TPF
chemotherapy is warranted.
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